EFI Lake Geneva Ventures

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Terapet SA, founded in 2019 in Geneva, Switzerland, specializes in proton therapy, an advanced form of radiotherapy for cancer treatment. Established by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals, the company aims to provide precise tumor targeting while minimizing damage to adjacent healthy tissues. Terapet's innovative technology allows for a reduced radiation dose to surrounding healthy cells by administering high doses of protons that halt at specific depths within the patient. This capability enables medical professionals to monitor the proton dose in real-time and in three dimensions, making cancer treatment more effective and potentially more cost-efficient. The company has successfully demonstrated the feasibility of its concept and is in the process of developing an initial version for market launch.